The most common approach for separating CTCs, which has shown prognostic value in some cancer types, is by using an antibody that targets the tumor cell specific surface antigens, such as epithelial cell adhesion molecule (EpCAM) [4,5,6,7,8]. This evidence concerns the gene EPCAM and neoplasm.